{"DataElement":{"publicId":"2982988","version":"1","preferredName":"Hematology Response Type","preferredDefinition":"the type related to hematologic response.","longName":"2014511v1.0:2982982v1.0","context":"CTEP","contextVersion":"2.31","DataElementConcept":{"publicId":"2014511","version":"1","preferredName":"Hematology Response","preferredDefinition":"the hematologic response.","longName":"HMT_RESP","context":"CTEP","contextVersion":"2.31","ObjectClass":{"publicId":"2760814","version":"1","preferredName":"Hematologic","preferredDefinition":"Pertaining to or related to the blood and blood-forming organs.","longName":"C62780","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hematologic","conceptCode":"C62780","definition":"Pertaining to or related to the blood and blood-forming organs.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"505BF29A-6085-1D44-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-06-23","endDate":null,"createdBy":"CZECHS","dateCreated":"2008-06-23","modifiedBy":"ONEDATA","dateModified":"2008-06-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2177336","version":"1","preferredName":"Response","preferredDefinition":"Response; a bodily process occurring due to the effect of some foregoing stimulus or agent.","longName":"Response","context":"CTEP","contextVersion":"2.31","Concepts":[{"longName":"Response","conceptCode":"C25755","definition":"Any act or phenomena, or behavior, constituting a reply or reaction of a living organism or its part to some foregoing stimulus or agent.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"AE29A78C-528C-3A05-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-10-29","endDate":null,"createdBy":"SBREXT","dateCreated":"2002-10-29","modifiedBy":"SBR","dateModified":"2005-03-29","changeDescription":"Denise Warzel updated Definition by seraching NCI Thesaurus in Admin tool.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008550","version":"1","preferredName":"Disease Response","preferredDefinition":"the response criteria (includes RECIST and others) and associated documentation of disease.","longName":"DZ_RESP","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22C0651-216B-5273-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B928A5FD-E8B4-1539-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2003-03-18","endDate":null,"createdBy":"MWHITE","dateCreated":"2003-03-18","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2982982","version":"1","preferredName":"Hematologic Response Type","preferredDefinition":"the type of hematologic response.","longName":"2982982v1.0","context":"CTEP","contextVersion":"2.31","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"35","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Minor response","valueDescription":"Minor response","ValueMeaning":{"publicId":"2576121","version":"1","preferredName":"Minor response","longName":"2576121","preferredDefinition":"Minor response","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F666-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-09-07","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-09-07","modifiedBy":"CAMPBELB","dateModified":"2005-09-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7C991ADD-0105-711A-E040-BB89AD432C85","beginDate":"2010-01-07","endDate":null,"createdBy":"ALAIS","dateCreated":"2010-01-07","modifiedBy":"ONEDATA","dateModified":"2010-01-07","deletedIndicator":"No"},{"value":"Very good partial response","valueDescription":"Very good partial response","ValueMeaning":{"publicId":"2955993","version":"1","preferredName":"Very good partial response","longName":"2955993","preferredDefinition":"VGPR  Very good partial response (VGPR) -- serum and urine M-protein\r\ndetectable by immunofixation but not on electrophoresis, or greater than or equal to 90%\r\nreduction in serum M-protein and urine M-protein level less than 100 mg/24\r\nhours\r\nVGPR requires two consecutive assessments made at any time\r\nbefore the institution of any new therapy, and no known evidence of\r\nprogressive or new bone lesions if radiographic studies were\r\nperformed; radiographic studies are not required to satisfy VGPR\r\nrequirements","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"76D78551-E8B6-AA5D-E040-BB89AD435A4F","latestVersionIndicator":"Yes","beginDate":"2009-10-26","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2009-10-26","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7C991ADD-0119-711A-E040-BB89AD432C85","beginDate":"2010-01-07","endDate":null,"createdBy":"ALAIS","dateCreated":"2010-01-07","modifiedBy":"ONEDATA","dateModified":"2010-01-07","deletedIndicator":"No"},{"value":"Amyloid complete response","valueDescription":"Amyloidogenesis Complete Remission","ValueMeaning":{"publicId":"2982984","version":"1","preferredName":"Amyloidogenesis Complete Remission","longName":"2982984","preferredDefinition":"Amyloidogenesis is the formation or growth of amyloid structures, implicated in many human diseases including Alzheimer s disease (AD), Parkinson s disease (PD), type II diabetes, and spongiform encephalopathies. In these disease states, normally soluble proteins aggregate as amyloidogenic insoluble fibrils that accumulate in affected tissues or organs.: The disappearance of all signs of cancer in response to treatment.  This does not always mean the cancer has been cured.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Amyloidogenesis","conceptCode":"C44955","definition":"Amyloidogenesis is the formation or growth of amyloid structures, implicated in many human diseases including Alzheimer s disease (AD), Parkinson s disease (PD), type II diabetes, and spongiform encephalopathies. In these disease states, normally soluble proteins aggregate as amyloidogenic insoluble fibrils that accumulate in affected tissues or organs.","evsSource":"RADLEX_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Complete Remission","conceptCode":"C4870","definition":"The disappearance of all signs of cancer in response to treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7C991ADD-0149-711A-E040-BB89AD432C85","latestVersionIndicator":"Yes","beginDate":"2010-01-07","endDate":null,"createdBy":"ALAIS","dateCreated":"2010-01-07","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7C991ADD-0162-711A-E040-BB89AD432C85","beginDate":"2010-01-07","endDate":null,"createdBy":"ALAIS","dateCreated":"2010-01-07","modifiedBy":"ONEDATA","dateModified":"2010-01-07","deletedIndicator":"No"},{"value":"Partial Remission","valueDescription":"Partial Remission","ValueMeaning":{"publicId":"2577916","version":"1","preferredName":"Partial Remission","longName":"2577916","preferredDefinition":"A decrease in the size of a tumor, or in the extent of cancer in the body, in response to treatment.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Partial Remission","conceptCode":"C18058","definition":"A finding indicating that there is a decrease in the size and the extent of tissue involvement by a malignant tumor in a patient.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FD69-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-02-24","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-02-24","modifiedBy":"ONEDATA","dateModified":"2006-02-24","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7C991ADD-016C-711A-E040-BB89AD432C85","beginDate":"2010-01-07","endDate":null,"createdBy":"ALAIS","dateCreated":"2010-01-07","modifiedBy":"ONEDATA","dateModified":"2010-01-07","deletedIndicator":"No"},{"value":"Stringent complete response","valueDescription":"Stringent Complete Response (sCR) of Multiple Myeloma or Plasma Cell Leukemia","ValueMeaning":{"publicId":"2982983","version":"1","preferredName":"Stringent Complete Response (sCR) of Multiple Myeloma or Plasma Cell Leukemia","longName":"2982983","preferredDefinition":"Stringent complete response (sCR) of multiple myeloma or plasma cell leukemia is characterized by complete response plus: normal free light chain ratio, and absence of clonal cells in the bone marrow by immunohistochemistry or immunofluorescence (confirmation with repeat bone marrow biopsy not needed). (Presence and/or absence of clonal cells is based upon the kappa/lambda ratio. An abnormal kappa/lambda ratio by immunohistochemistry and/or immunofluorescence requires a minimum of 100 plasma cells for analysis. An abnormal ratio reflecting the presence of an abnormal clone is kappa/lambda of > 4:1 or < 1:2.).  Stringent complete response requires two consecutive assessments made at any time before the institution of any new therapy, and no known evidence of progressive or new bone lesions if radiographic studies were performed; radiographic studies are not required to satisfy stringent complete response requirements.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stringent Complete Response (sCR) of Multiple Myeloma or Plasma Cell Leukemia","conceptCode":"C70637","definition":"Stringent complete response (sCR) of multiple myeloma or plasma cell leukemia is characterized by complete response plus: normal free light chain ratio, and absence of clonal cells in the bone marrow by immunohistochemistry or immunofluorescence (confirmation with repeat bone marrow biopsy not needed). (Presence and/or absence of clonal cells is based upon the kappa/lambda ratio. An abnormal kappa/lambda ratio by immunohistochemistry and/or immunofluorescence requires a minimum of 100 plasma cells for analysis. An abnormal ratio reflecting the presence of an abnormal clone is kappa/lambda of > 4:1 or < 1:2.).  Stringent complete response requires two consecutive assessments made at any time before the institution of any new therapy, and no known evidence of progressive or new bone lesions if radiographic studies were performed; radiographic studies are not required to satisfy stringent complete response requirements.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7C991ADD-0123-711A-E040-BB89AD432C85","latestVersionIndicator":"Yes","beginDate":"2010-01-07","endDate":null,"createdBy":"ALAIS","dateCreated":"2010-01-07","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7C991ADD-013B-711A-E040-BB89AD432C85","beginDate":"2010-01-07","endDate":null,"createdBy":"ALAIS","dateCreated":"2010-01-07","modifiedBy":"ONEDATA","dateModified":"2010-01-07","deletedIndicator":"No"},{"value":"No response stable disease","valueDescription":"Stable Disease","ValueMeaning":{"publicId":"2982985","version":"1","preferredName":"Stable Disease","longName":"2982985","preferredDefinition":"Cancer that is neither decreasing nor increasing in extent or severity.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stable Disease","conceptCode":"C18213","definition":"A disease that is neither decreasing nor increasing in extent or severity.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7C991ADD-0176-711A-E040-BB89AD432C85","latestVersionIndicator":"Yes","beginDate":"2010-01-07","endDate":null,"createdBy":"ALAIS","dateCreated":"2010-01-07","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7C991ADD-018E-711A-E040-BB89AD432C85","beginDate":"2010-01-07","endDate":null,"createdBy":"ALAIS","dateCreated":"2010-01-07","modifiedBy":"ONEDATA","dateModified":"2010-01-07","deletedIndicator":"No"},{"value":"Hematologic progressive disease","valueDescription":"Hematologic PD","ValueMeaning":{"publicId":"2982986","version":"1","preferredName":"Hematologic PD","longName":"2982986","preferredDefinition":"Pertaining to or related to the blood and blood-forming organs.: Cancer that is increasing in scope or severity.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hematologic","conceptCode":"C62780","definition":"Pertaining to or related to the blood and blood-forming organs.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Progressive Disease","conceptCode":"C35571","definition":"A clinical, pathologic, and/or molecular finding indicating that the course of a disease is worsening in terms of extent or severity.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7C991ADD-019C-711A-E040-BB89AD432C85","latestVersionIndicator":"Yes","beginDate":"2010-01-07","endDate":null,"createdBy":"ALAIS","dateCreated":"2010-01-07","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7C991ADD-01B5-711A-E040-BB89AD432C85","beginDate":"2010-01-07","endDate":null,"createdBy":"ALAIS","dateCreated":"2010-01-07","modifiedBy":"ONEDATA","dateModified":"2010-01-07","deletedIndicator":"No"},{"value":"Partial Response","valueDescription":"Partial Remission","ValueMeaning":{"publicId":"2577916","version":"1","preferredName":"Partial Remission","longName":"2577916","preferredDefinition":"A decrease in the size of a tumor, or in the extent of cancer in the body, in response to treatment.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Partial Remission","conceptCode":"C18058","definition":"A finding indicating that there is a decrease in the size and the extent of tissue involvement by a malignant tumor in a patient.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FD69-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-02-24","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-02-24","modifiedBy":"ONEDATA","dateModified":"2006-02-24","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7CE5ED33-7015-0231-E040-BB89AD435A9D","beginDate":"2010-01-07","endDate":null,"createdBy":"ALAIS","dateCreated":"2010-01-11","modifiedBy":"ONEDATA","dateModified":"2010-01-11","deletedIndicator":"No"},{"value":"Complete Response","valueDescription":"Complete Remission","ValueMeaning":{"publicId":"3090976","version":"1","preferredName":"Complete Remission","longName":"3090976","preferredDefinition":"The disappearance of all signs of cancer in response to treatment.  This does not always mean the cancer has been cured.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Complete Remission","conceptCode":"C4870","definition":"The disappearance of all signs of cancer in response to treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"871570E4-2901-7B29-E040-BB89AD43510F","latestVersionIndicator":"Yes","beginDate":"2010-05-21","endDate":null,"createdBy":"ALAIS","dateCreated":"2010-05-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"871570E4-2919-7B29-E040-BB89AD43510F","beginDate":"2010-05-21","endDate":null,"createdBy":"ALAIS","dateCreated":"2010-05-21","modifiedBy":"ONEDATA","dateModified":"2010-05-21","deletedIndicator":"No"},{"value":"Unevaluable","valueDescription":"Unevaluable","ValueMeaning":{"publicId":"2570773","version":"1","preferredName":"Unevaluable","longName":"2570773","preferredDefinition":"Unevaluable","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-E182-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-06-21","endDate":null,"createdBy":"SBR","dateCreated":"2004-06-21","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"871570E4-28E2-7B29-E040-BB89AD43510F","beginDate":"2010-05-21","endDate":null,"createdBy":"ALAIS","dateCreated":"2010-05-21","modifiedBy":"ONEDATA","dateModified":"2010-05-21","deletedIndicator":"No"},{"value":"No response/stable disease","valueDescription":"Stable Disease","ValueMeaning":{"publicId":"2982985","version":"1","preferredName":"Stable Disease","longName":"2982985","preferredDefinition":"Cancer that is neither decreasing nor increasing in extent or severity.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stable Disease","conceptCode":"C18213","definition":"A disease that is neither decreasing nor increasing in extent or severity.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7C991ADD-0176-711A-E040-BB89AD432C85","latestVersionIndicator":"Yes","beginDate":"2010-01-07","endDate":null,"createdBy":"ALAIS","dateCreated":"2010-01-07","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"871570E4-28F7-7B29-E040-BB89AD43510F","beginDate":"2010-01-07","endDate":null,"createdBy":"ALAIS","dateCreated":"2010-05-21","modifiedBy":"ONEDATA","dateModified":"2010-05-21","deletedIndicator":"No"},{"value":"Progressive Disease","valueDescription":"PD","ValueMeaning":{"publicId":"3090977","version":"1","preferredName":"PD","longName":"3090977","preferredDefinition":"A disease process that is increasing in scope or severity.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Progressive Disease","conceptCode":"C35571","definition":"A clinical, pathologic, and/or molecular finding indicating that the course of a disease is worsening in terms of extent or severity.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"871570E4-2924-7B29-E040-BB89AD43510F","latestVersionIndicator":"Yes","beginDate":"2010-05-21","endDate":null,"createdBy":"ALAIS","dateCreated":"2010-05-21","modifiedBy":"COOPERM","dateModified":"2019-03-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"871570E4-293C-7B29-E040-BB89AD43510F","beginDate":"2010-05-21","endDate":null,"createdBy":"ALAIS","dateCreated":"2010-05-21","modifiedBy":"ONEDATA","dateModified":"2010-05-21","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008550","version":"1","preferredName":"Disease Response","preferredDefinition":"the response criteria (includes RECIST and others) and associated documentation of disease.","longName":"DZ_RESP","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22C0651-216B-5273-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2234813","version":"1","preferredName":"Type","preferredDefinition":"Type; a subdivision of a particular kind of thing.","longName":"C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"F970CDF6-F90E-21D3-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-14","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-06-14","modifiedBy":"SBR","dateModified":"2005-09-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"ECOG CRF:Eastern Cooperative Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"7C991ADD-00E5-711A-E040-BB89AD432C85","latestVersionIndicator":"Yes","beginDate":"2010-01-07","endDate":null,"createdBy":"ALAIS","dateCreated":"2010-01-07","modifiedBy":"ALAIS","dateModified":"2010-05-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[],"ReferenceDocuments":[{"name":"CRF Text1","type":"Alternate Question Text","description":"Objective status at this evaluation","url":null,"context":"CTEP"},{"name":"Objective hematologic status","type":"Preferred Question Text","description":"Objective hematologic status at this evaluation","url":null,"context":"CTEP"}],"origin":"ECOG CRF:Eastern Cooperative Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"7C991ADD-01BF-711A-E040-BB89AD432C85","latestVersionIndicator":"Yes","beginDate":"2010-01-07","endDate":null,"createdBy":"ALAIS","dateCreated":"2010-01-07","modifiedBy":"ALAIS","dateModified":"2010-05-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}